Thursday, 20 Feb 2020

You are here

Antibodies to 14-3-3η Found in Large Vessel Vasculitis

14-3-3η (eta) is a new test that may be useful in diagnosing patients with early rheumatoid arthritis. The test is 77% sensitive and 93% specific for RA and developers have found that antibodies against 14-3-3η may correlate with drug responsiveness.

Researchers from Cleveland Clinic examined aorta samples from 11 patients with large vessel vasculitis (LVV) and 11 controls and also examined sera from 23 LVV and matched controls and demonstrated that 78% of patients with large vessel vasculitis have antibodies to 14-3-3η.

14-3-3η is one isoform from a family of chaperone proteins involved in intracellular and extracellular signaling. 14-3-3η is not known to have a pathogenic role in RA but has also been shown to induce numerous proinflammatory mediators. The role of antibodies against 14-3-3η in the pathogenesis of vasculitis is unknown and merits further study.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

BSR Guidelines for Giant Cell Arteritis

NICE has commissioned an update to the 2010 British Society for Rheumatology guideline for the management of giant cell arteritis, and proposed a total of 19 recommendations for the diagnosis and treatment of GCA.

PEXIVAS - Plasma Exhange Fails to Boost Outcomes in Severe AAV

The PEXIVAS study showed that plasma exchange did not reduce the incidence of death or ESKD in patients with severe ANCA–associated vasculitis.

Shingles Vaccine Lowers Risk of CVA

Shingles infection has been historically linked to an increased risk of stroke. A new study found that Zoster Vaccine Live, one type of shingles vaccination, may prevent stroke in some older adults.

EULAR Recommendations on Sjögren’s Syndrome

The European League Against Rheumatism (EULAR) has established an international collaborative group (EULAR SS Task Force) to develop the first EULAR evidence and consensus-based recommendations for the management of patients with Sjogens syndrome (SjS).

Steroid-Sparing Effect of Tocilizumab in Refractory Takayasu Arteritis

A controlled clinical trial has shown that giving the IL-6 receptor antibody, tocilizumab (TCZ), to  patients with Takayasu arteritis (TAK) results in clinical efficacy and has a steroid sparing efffect.